These subgroups include patients with inflammatory carcinoma, locally advanced carcinoma, occult carcinoma, and those with persistent suspicious pathological nodes after NAC, as assessed by ultrasonography, particularly in HER2-positive and triple-negative breast cancer phenotypes. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.